DAB2 Suppresses Gastric Cancer Migration by Regulating the Wnt/β-catenin and Hippo-YAP Signaling Pathways

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117462

Authors

Hua Wang

Surong Dong

Yun Liu

Feng Ma

Jian Fang

Wentao Zhang

Shihe Shao

Hongxing Shen

Jingpeng Jin

Affiliations

Soon will be listed here.

Abstract

Background: Disabled-2 (DAB2), a potential tumor suppressor, plays an in important role in cancer development and cellular differentiation. Its lower expression levels have founded in many cancers. In addition, DAB2 is involved in multiple signaling pathways, including TGF-β and Wnt signal pathways. Gastric cancer (GC) is a common gastrointestinal malignant tumor. Nonetheless, the role of DAB2 in GC remains unclear.

Methods: Thirty-seven clinical specimens of GC tissues and adjacent non-tumor tissues were examined by immunohistochemistry. Proteins were extracted from two of them to perform Western blot analysis. Then, CMV-MCS-3FLAG-SV40-DAB2 and si-DAB2 were transfected into MGC and SGC cell line, respectively. The migration of GC cells was evaluated by transwell migration assay. And, the expression of migration related proteins was detected by Western blot and immunofluorescence (IF).

Results: Eighty-six percent (32/37) of patients DAB2 staining was reduced in GC tissues compared to adjacent normal tissues. Further studies showed that in six human GC cell lines, the level of DAB2 expression was lower than normal gastric epithelial cells, and that DAB2 was closely related to cell migration . In DAB2 silenced cells, the Wnt/β-catenin signaling was increased and the Hippo-YAP pathway was affected. In addition, lower DAB2 level led to nuclear translocation of β-catenin and Yap.

Conclusions: The lower expression of DAB2 regulates cell migration in GC via interfering with the Wnt and Hippo signaling pathway. Our findings suggested that DAB2 played an important role in the migration of GC.

Citing Articles

Single-cell RNA-sequencing and genome-wide Mendelian randomisation along with abundant machine learning methods identify a novel B cells signature in gastric cancer.

Ma Q, Gao J, Hui Y, Zhang Z, Qiao Y, Yang B Discov Oncol. 2025; 16(1):11.

PMID: 39760915 PMC: 11703799. DOI: 10.1007/s12672-025-01759-1.

The scaffold protein disabled 2 (DAB2) and its role in tumor development and progression.

Pandya D, Parikh R, Gena R, Kothari N, Parekh P, Chorawala M Mol Biol Rep. 2024; 51(1):701.

PMID: 38822973 DOI: 10.1007/s11033-024-09653-9.

Identification of the role of DAB2 and CXCL8 in uterine spiral artery remodeling in early-onset preeclampsia.

Liu Y, Du L, Gu S, Liang J, Huang M, Huang L Cell Mol Life Sci. 2024; 81(1):180.

PMID: 38613672 PMC: 11016014. DOI: 10.1007/s00018-024-05212-4.

Disable 2, A Versatile Tissue Matrix Multifunctional Scaffold Protein with Multifaceted Signaling: Unveiling Role in Breast Cancer for Therapeutic Revolution.

Shah N, Dave B, Shah K, Shah D, Maheshwari K, Chorawala M Cell Biochem Biophys. 2024; 82(2):501-520.

PMID: 38594547 DOI: 10.1007/s12013-024-01261-5.

Disabled-2, a versatile tissue matrix multifunctional scaffold protein with multifaceted signaling: Unveiling its potential in the cancer battle.

Shah N, Dave B, Shah K, Shah D, Maheshwari K, Chorawala M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(8):5533-5557.

PMID: 38502243 DOI: 10.1007/s00210-024-03037-3.

References

Zhou Z, Zhu J, Gao C, Li L, Zhou C, Wang H . siRNA targeting YAP gene inhibits gastric carcinoma growth and tumor metastasis in SCID mice. Oncol Lett. 2016; 11(4):2806-2814. PMC: 4812121. DOI: 10.3892/ol.2016.4319. View

Anupam K, Tusharkant C, Gupta S, Ranju R . Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol. 2006; 12(37):6041-5. PMC: 4124415. DOI: 10.3748/wjg.v12.i37.6041. View

Rosenbauer F, Kallies A, Scheller M, Knobeloch K, Rock C, Schwieger M . Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion. EMBO J. 2002; 21(3):211-20. PMC: 125345. DOI: 10.1093/emboj/21.3.211. View

Hofsteen P, Robitaille A, Chapman D, Moon R, Murry C . Quantitative proteomics identify DAB2 as a cardiac developmental regulator that inhibits WNT/β-catenin signaling. Proc Natl Acad Sci U S A. 2016; 113(4):1002-7. PMC: 4743825. DOI: 10.1073/pnas.1523930113. View

Hocevar B, Mou F, Rennolds J, Morris S, Cooper J, Howe P . Regulation of the Wnt signaling pathway by disabled-2 (Dab2). EMBO J. 2003; 22(12):3084-94. PMC: 162138. DOI: 10.1093/emboj/cdg286. View

Chu D, Zhu S, Li J, Ji G, Wang W, Wu G . CD147 expression in human gastric cancer is associated with tumor recurrence and prognosis. PLoS One. 2014; 9(6):e101027. PMC: 4076217. DOI: 10.1371/journal.pone.0101027. View

Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi M . The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. J Med Chem. 2015; 58(12):4857-73. DOI: 10.1021/jm501615v. View

Liu J, Li Y, Lin H, Liao Y, Mai S, Liu Z . Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 2013; 13:349. PMC: 3750259. DOI: 10.1186/1471-2407-13-349. View

Fernandez-L A, Squatrito M, Northcott P, Awan A, Holland E, Taylor M . Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 2011; 31(15):1923-37. PMC: 3583298. DOI: 10.1038/onc.2011.379. View

10.

Wang W, Chang W, Yang H, Wang Y, Chang I, Lee C . Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma. Oncotarget. 2016; 7(44):71169-71181. PMC: 5342070. DOI: 10.18632/oncotarget.8460. View

11.

Smyth E, Cunningham D . Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology. Nat Rev Clin Oncol. 2013; 10(2):73-4. DOI: 10.1038/nrclinonc.2012.228. View

12.

Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S . YAP/TAZ incorporation in the β-catenin destruction complex orchestrates the Wnt response. Cell. 2014; 158(1):157-70. DOI: 10.1016/j.cell.2014.06.013. View

13.

Zhou J, Scholes J, Hsieh J . Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem. 2002; 278(9):6936-41. DOI: 10.1074/jbc.M210628200. View

14.

Hocevar B . Loss of Disabled-2 Expression in Pancreatic Cancer Progression. Sci Rep. 2019; 9(1):7532. PMC: 6525241. DOI: 10.1038/s41598-019-43992-z. View

15.

Chetrit D, Ziv N, Ehrlich M . Dab2 regulates clathrin assembly and cell spreading. Biochem J. 2008; 418(3):701-15. DOI: 10.1042/BJ20081288. View

16.

Mi Y, Zhao S, Zhou C, Weng J, Li J, Wang Z . Downregulation of homeobox gene Barx2 increases gastric cancer proliferation and metastasis and predicts poor patient outcomes. Oncotarget. 2016; 7(37):60593-60608. PMC: 5312404. DOI: 10.18632/oncotarget.11260. View

17.

Li C, Chen J, Chen T, Xu Z, Xu C, Ding C . Aberrant Hypermethylation at Sites -86 to 226 of DAB2 Gene in Non-Small Cell Lung Cancer. Am J Med Sci. 2015; 349(5):425-31. DOI: 10.1097/MAJ.0000000000000436. View

18.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

19.

Karam J, Shariat S, Huang H, Pong R, Ashfaq R, Shapiro E . Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res. 2007; 13(15 Pt 1):4400-6. DOI: 10.1158/1078-0432.CCR-07-0287. View

20.

Jiang Y, He X, Howe P . Disabled-2 (Dab2) inhibits Wnt/β-catenin signalling by binding LRP6 and promoting its internalization through clathrin. EMBO J. 2012; 31(10):2336-49. PMC: 3364753. DOI: 10.1038/emboj.2012.83. View